Strategies for Successful Management of Severe Atopic Dermatitis.
Atopic dermatitis
Biologics
Dupilumab
Eczema
Wet wrap therapy
Journal
The journal of allergy and clinical immunology. In practice
ISSN: 2213-2201
Titre abrégé: J Allergy Clin Immunol Pract
Pays: United States
ID NLM: 101597220
Informations de publication
Date de publication:
01 2019
01 2019
Historique:
received:
11
09
2018
revised:
18
10
2018
accepted:
22
10
2018
entrez:
2
1
2019
pubmed:
2
1
2019
medline:
6
5
2020
Statut:
ppublish
Résumé
Patients with severe atopic dermatitis (AD) are reported to represent between 10% and 18% of all patients with AD. However, in this subgroup of patients, quality of life is significantly affected and patients may have a number of atopic and nonatopic comorbidities. Treatment of this severe population has often been reactive with inappropriate use of systemic corticosteroids and unapproved immunosuppressants. Recent insights point to the systemic nature of AD, which has important therapeutic implications. Management of severe AD requires a comprehensive approach that incorporates proper diagnosis, assessment of disease severity, and impact on patient's and caregiver's quality of life, along with education regarding the chronic relapsing nature of the disease as well as treatment options. Biologics such as dupilumab offer a novel, targeted therapeutic approach for this systemic disease.
Identifiants
pubmed: 30598172
pii: S2213-2198(18)30678-0
doi: 10.1016/j.jaip.2018.10.021
pii:
doi:
Substances chimiques
Antibodies, Monoclonal, Humanized
0
Biological Products
0
dupilumab
420K487FSG
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
1-16Informations de copyright
Copyright © 2019. Published by Elsevier Inc.